Preclinical research comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-08. Numbers and descriptions here follow the published literature rather than marketing material.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Typical form of reference material |
| Solubility | Low in water; soluble in DMSO | Used to prepare stock solutions |
| Typical storage | -20 °C, desiccated, protected from light | Common laboratory practice |
| Analytical method | LC-MS/MS | Detects parent compound and metabolites |
| Common test matrix | Urine or blood | Used in anti-doping analysis |
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
=== Cation exchange resins === Strong acid cation (SAC) resins: Composed of a polystyrene matrix with a sulphonate (SO3−) functional group. Used in softening or demineralization processes. Weak acid cation (WAC) resins: Composed of an acrylic polymer and carboxylic acid functional groups. Used to selectively remove cations associated with alkalinity.
Head, Children and Young People's Service, The Rathbone Society. For services to Young People. Penelope Anne Kirby. For services to Mountain Rescue in the Lake District. Henry James Kissock. Information and Communication Technology Service Delivery Manager, Police Service of Northern Ireland. For services to the community in Northern Ireland. Melissa Kose. Emerging Talent Manager, British Airways. For services to Early Careers in Aviation. Mostaque Ahmed Koyes. Director, Community Interest Luton. For services to the community in Luton, Bedfordshire. Anna Ruth Ella Lapwood. Organist. For services to Music. Harriet Hannah Laurie. Founder, TheHorseCourse. For services to Disadvantaged People in Dorset. Jayne Anne Law. Lately Head of Honours and the Kings Award for Voluntary Service, Department for Culture, Media and Sport. For Public Service. Dr. Fenella Kate Leach (Fenella Wrigley). Chief Medical Officer and Deputy Chief Executive, London Ambulance Service NHS Trust. For services to the NHS. Helen Margaret Leadbitter. For services to Young Carers. Aryeh Leaman. For services to Young People and to the community in Hendon, London Borough of Barnet. Jeremy James Lee. Chef. For services to the Food Industry. David Levy. Senior Community Outreach Adviser, Ukraine Humanitarian Taskforce, Department for Levelling Up, Housing and Communities. For services to Refugee Resettlement. Andrew Colin MacDuff Liddell. Lately Charity Lawyer, Pitlochry. For services to Theatre and the Arts in Scotland. Fiona Ann Lindop.
== Complications == LA-ICP-MS function optimally with gold particles greater than 60 μm in diameter to avoid any contamination during measurements. Although LA-ICP-MS has a lower detection limit, its overall precision was lower than other analysis techniques for trace element concentrations such as field emission-electron probe microanalysis (FE-EPMA) and synchrotron micro X-ray fluorescence spectroscopy (SR-l-XRF). Due to the small size of gold (<5μm-250μm) small fragments of minerals need to be separated from the gold before analysis can occur. Gold fingerprinting has limitations including elemental fractionation (the non-sample related analyte) and calibration requires matrix-matched standards. A few other problems exist that limit actual sourcing or provencancing of gold in relation to manufactured art objects. These problems include: a lack of an extensive database of elemental profiles in gold ores, the natural differences that coexist in ore geology and the difficulties of accurately analyzing trace elements. Also, trading, looting and re-melting of so called “precious” metal objects add to the problem of sourcing.
Sources: en.wikipedia.org
== Other uses == Relief pitcher, a baseball term Registered Paralegal, a certification program of the National Federation of Paralegal Associations Riot Points (used in League of Legends) Regimental Police or Regimental Provost, soldiers responsible for regimental discipline and unit custody in the British Army Role-playing Rating Pending, a rating used by ESRB in promotional games that has lacked a rating.
It has been proved that pravastatin and zoledronate are effective drugs when it comes to the blocking of farnesyl group production. Farnesyltransferase inhibitors (FTIs) are drugs that inhibit the activity of an enzyme needed to make a link between progerin proteins and farnesyl groups. This link generates the permanent attachment of the progerin to the nuclear rim. In progeria, cellular damage can occur because that attachment occurs, and the nucleus is not in a normal state. Lonafarnib is an FTI, which means it can avoid this link, so progerin can not remain attached to the nucleus rim, and it now has a more normal state. Studies of sirolimus, an mTOR Inhibitor, demonstrate that it can minimize the phenotypic effects of progeria fibroblasts. Other observed consequences of its use are abolishing nuclear blebbing, degradation of progerin in affected cells, and reducing insoluble progerin aggregates formation. These results have been observed only in vitro and are not the results of any clinical trial, although it is believed that the treatment might benefit HGPS patients. Recently, it has been demonstrated that the CRM1 protein (a key component of the nuclear export machinery in mammalian) is upregulated in HGPS cells, which drives to the abnormal localization of NES containing proteins from the nucleus to the cytoplasm. Moreover, the inhibition of CRM1 in HGPS alleviates the associated-senescence phenotype as well as the mitochondrial function (an important determinant in senescence) and lysosome content.
== Refining the techniques == The next development was gas chromatography (GC). Martin and Synge had predicted its principles in their 1941 paper. Erika Cremer laid the theoretical basis of GC in 1944. Austrian chemist Fritz Prior, under the direction of Erika Cremer, constructed in 1947 the first prototype of a gas chromatograph and achieved separating oxygen and carbon dioxide, in 1947 during his Ph.D. research. Beginning in 1949, Martin and Anthony T. James worked on developing GC. At his 1952 Nobel lecture, Martin announced the successful separation of a wide variety of natural compounds by GC. GC was quickly adopted since it is easy and efficient for separating organic chemicals, and new detection methods for analyzing the output were quickly developed. The thermal conductivity detector, described in 1954 by N. H. Ray, was the foundation for several other methods: the flame ionization detector by J. Harley, W. Nel, and V. Pretorius in 1958, and the electron capture detector by James Lovelock in 1958. Others introduced mass spectrometers to gas chromatography in the late 1950s. The work of Martin and Synge also set the stage for high performance liquid chromatography (HPLC), suggesting that small sorbent particles and pressure could produce fast liquid chromatography techniques. This became widely practical by the late 1960s (and the method was used to separate amino acids as early as 1960).
Sources: en.wikipedia.org
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.
PPARδ is a nuclear receptor that regulates genes linked to fatty acid oxidation and energy metabolism. Activation can alter lipid handling and energy use in experimental models. The full range of effects in humans is still under study.
The solid compound is generally stable when kept cold, dry, and protected from light. Solutions may degrade faster, so laboratory protocols often specify fresh preparation or cold storage. Stability can depend on solvent, concentration, and container.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.